摘要
Abstract
Objective To analyze the effect of montelukast combined with budesonide on serum immuno-globulin E (IgE) and pulmonary function in children with asthma, to explore its clinical application value. Method 164 cases of children with asthma in our hospital from March 2013 to March 2016 were randomly divided into observation group and control group, 82 cases in each group. They were treated with budesonide inhalation therapy and routine spasmolysis, expectorant treatment, observation group children were treated with montelukast orally. The clinical efficacy, adverse reactions and changes of serum IgE level and pulmonary function betwee the two groups were compared, and the efficacy and safety of the combined drug regimen were defined. Result 164 cases of children were successfully completed 2 months of treatment. The total effective rate of observation group [92.68% (76/82)] was higher than control group [73.17% (60/82)] (P < 0.05). The incidence of adverse reactions of observation group was 3.66% (3/82), control group was 4.88% (4/82), the incidence of adverse reactions between the two groups was not statistically significant (χ2 = 0.275, P >0.05). After treatment, the serum levels of IgE in the two groups were decreased, FEV1, FVC and PEF were all increased, and the changes of observation group was more obvious, the differences were statistically significant (P < 0.05). Conclusion Montelukast combined with budesonide can significantly improve the level of serum IgE and lung function in children with asthma, and on the basis to ensure the safety of the treatment on effectively improve the clinical curative effect, which is of positive significance to the improvement of symptoms.关键词
孟鲁司特钠/布地奈德/哮喘/免疫球蛋白 E/肺功能Key words
Montelukast/Budesonide/Asthma/Immunoglobulin E/Pulmonary function
